Zepbound (tirzepatide) is FDA approved for chronic weight management in adults with obesity or overweight plus a weight related condition. It is the same molecule as Mounjaro which is FDA approved for Type 2 diabetes. The timeline is identical to Mounjaro because they are the same drug.
This guide walks through each phase, factors that change your timeline, and how meal delivery supports Zepbound users.
Appetite suppression begins in the first week at 2.5 mg. Tirzepatide acts on both GLP 1 and GIP receptors which produces stronger appetite suppression than semaglutide. Most users describe smaller portions and reduced hunger within 5 to 10 days. The 2.5 mg starting dose is a tolerance ramp.
Significant weight loss begins after dose escalation to 5 mg at week 5. SURMOUNT 1 showed average 8 to 12 percent loss at week 12 on the 10 mg dose, with continued loss as the dose climbs.
Full effect at 15 mg maintenance is reached around week 21. SURMOUNT 1 showed average 20.9 percent body weight loss at 72 weeks. Plateaus are common after month 9 to 12 and often resolve with continued behavior reinforcement.
| Week | Dose | Typical effect |
|---|---|---|
| Weeks 1 to 4 | 2.5 mg weekly | Tolerance ramp. Appetite drops. Weight loss 1 to 4 pounds. |
| Weeks 5 to 8 | 5 mg weekly | Therapeutic dose. Weight loss 1 to 2 pounds per week. |
| Weeks 9 to 12 | 7.5 mg weekly | Continued loss, side effects often peak. |
| Weeks 13 to 16 | 10 mg weekly | Common maintenance for many patients. |
| Weeks 17 to 20 | 12.5 mg weekly | Climbing to full dose. |
| Weeks 21+ | 15 mg weekly (maintenance) | Full effect. Average 20.9 percent loss at 72 weeks. |
Zepbound users need consistent protein during the strong appetite suppression phases. Meal delivery removes the planning load when cooking is the last thing you want to do.
Full ranking at our GLP 1 meal delivery hub.
Appetite suppression starts in the first week. Measurable weight loss by weeks 4 to 8. Full 15 mg effect reached around week 21.
Yes. Same molecule (tirzepatide). Mounjaro is FDA approved for Type 2 diabetes, Zepbound for chronic weight management. Timeline and effects are identical.
SURMOUNT 1 trial average is 20.9 percent body weight loss at 72 weeks on the 15 mg dose. Individual results vary.
Generally yes. Tirzepatide (Zepbound) trial data shows larger average weight loss than semaglutide (Wegovy) at comparable maintenance doses.
Most users plateau at month 9 to 14. Plateaus do not mean the medication has stopped working. They typically resolve with continued effort or dose adjustment.
Common reasons: still in escalation phase, low protein intake, poor sleep, plateau at month 9+. Discuss with prescriber if no change after 16 weeks at a stable dose.
Answer 5 quick questions. We'll match you to the top 3 from 24 services we track.